ARHGAP9

Across TCGA pan-cancer cohorts, ARHGAP9 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARHGAP9 data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ARHGAP9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARHGAP9 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LSCC show a favorable association.

GBM, UCEC, and PDAC are the cancer types where ARHGAP9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.602	0.798	.008	8	view →
UCEC	OS	Median	II,III,IV	1.000	0.628	.013	4	view →
PDAC	OS	Median	All	0.693	0.937	.034	4	view →
HNSC	DFS	Tertile	II,III,IV	0.901	0.989	.047	2	view →
LSCC	OS	Median	III,IV	0.951	0.758	.024	2	view →
LUAD	OS	Tertile	III,IV	0.314	0.768	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ARHGAP9–GBM (DFS)

Open the GBM breakdown →